NZ725492A - 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders - Google Patents
2,4-thiazolidinedione derivatives in the treatment of central nervous system disordersInfo
- Publication number
- NZ725492A NZ725492A NZ725492A NZ72549215A NZ725492A NZ 725492 A NZ725492 A NZ 725492A NZ 725492 A NZ725492 A NZ 725492A NZ 72549215 A NZ72549215 A NZ 72549215A NZ 725492 A NZ725492 A NZ 725492A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- disease
- nervous system
- central nervous
- system disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382130 | 2014-04-02 | ||
| PCT/EP2015/057224 WO2015150476A1 (en) | 2014-04-02 | 2015-04-01 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ725492A true NZ725492A (en) | 2023-06-30 |
Family
ID=50513194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ725492A NZ725492A (en) | 2014-04-02 | 2015-04-01 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
Country Status (24)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| JP6800013B2 (ja) * | 2013-03-14 | 2020-12-16 | ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ | 重水素化２，４−チアゾリジンジオン及び治療方法 |
| EP3666273A3 (en) | 2014-01-15 | 2020-10-28 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| HUE055351T2 (hu) * | 2014-04-02 | 2022-05-28 | Minoryx Therapeutics S L | 2,4-Tiazolidindion-származékok a központi idegrendszeri rendellenességek kezelésében |
| EP3548026B1 (en) | 2016-12-01 | 2021-01-20 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease |
| PL3559010T3 (pl) * | 2016-12-23 | 2022-11-21 | Minoryx Therapeutics S.L. | Sposób wytwarzania 5-[[4-[2-[5-(1-hydroksyetylo)-2-pirydynylo]etoksy]fenylo]metylo]-2,4-tiazolidynodionu i jego soli |
| FI3801515T3 (fi) | 2018-06-06 | 2025-05-27 | Minoryx Therapeutics S L | 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa |
| BR112020024939A2 (pt) * | 2018-06-06 | 2021-03-09 | Minoryx Therapeutics S.L. | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]benzil]-1,3-tiazolidina-2,4-diona e seus sais |
| EP3801516A1 (en) | 2018-06-06 | 2021-04-14 | Minoryx Therapeutics S.L. | Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| MX2022013021A (es) | 2020-04-30 | 2023-01-16 | Minoryx Therapeutics S L | Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| WO2024141951A1 (en) | 2022-12-28 | 2024-07-04 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| AU2024268104A1 (en) | 2023-05-09 | 2025-11-27 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| EP0579733B1 (en) * | 1991-04-11 | 2001-06-20 | PHARMACIA & UPJOHN COMPANY | Thiazolidinedione derivatives, production and use thereof |
| WO1993022445A1 (en) * | 1992-05-05 | 1993-11-11 | The Upjohn Company | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| WO2003055485A1 (en) | 2001-12-21 | 2003-07-10 | Smithkline Beecham Corporation | Dosing regimen for ppar-gamma activators |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| WO2005016339A1 (en) * | 2003-07-24 | 2005-02-24 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
| ES2654908T3 (es) * | 2006-03-16 | 2018-02-15 | Metabolic Solutions Development Company Llc | Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| EP3202401B1 (en) * | 2009-12-15 | 2019-10-23 | Cirius Therapeutics, Inc. | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en) * | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| JP6800013B2 (ja) | 2013-03-14 | 2020-12-16 | ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ | 重水素化２，４−チアゾリジンジオン及び治療方法 |
| EP3666273A3 (en) | 2014-01-15 | 2020-10-28 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| HUE055351T2 (hu) * | 2014-04-02 | 2022-05-28 | Minoryx Therapeutics S L | 2,4-Tiazolidindion-származékok a központi idegrendszeri rendellenességek kezelésében |
-
2015
- 2015-04-01 HU HUE18173541A patent/HUE055351T2/hu unknown
- 2015-04-01 WO PCT/EP2015/057224 patent/WO2015150476A1/en not_active Ceased
- 2015-04-01 ES ES18173541T patent/ES2872335T3/es active Active
- 2015-04-01 MX MX2016012687A patent/MX373234B/es active IP Right Grant
- 2015-04-01 DK DK15713499.0T patent/DK3125888T3/en active
- 2015-04-01 EP EP15713499.0A patent/EP3125888B1/en active Active
- 2015-04-01 HU HUE15713499A patent/HUE039555T2/hu unknown
- 2015-04-01 SI SI201530325T patent/SI3125888T1/en unknown
- 2015-04-01 PT PT181735416T patent/PT3388064T/pt unknown
- 2015-04-01 EP EP18173541.6A patent/EP3388064B1/en active Active
- 2015-04-01 AU AU2015239112A patent/AU2015239112C1/en active Active
- 2015-04-01 NZ NZ725492A patent/NZ725492A/en unknown
- 2015-04-01 SG SG11201608218QA patent/SG11201608218QA/en unknown
- 2015-04-01 DK DK18173541.6T patent/DK3388064T3/da active
- 2015-04-01 EA EA201691997A patent/EA035866B1/ru unknown
- 2015-04-01 KR KR1020167030649A patent/KR102418167B1/ko active Active
- 2015-04-01 HR HRP20180983TT patent/HRP20180983T1/hr unknown
- 2015-04-01 SI SI201531591T patent/SI3388064T1/sl unknown
- 2015-04-01 CA CA2943373A patent/CA2943373C/en active Active
- 2015-04-01 PL PL18173541T patent/PL3388064T3/pl unknown
- 2015-04-01 EA EA202091120A patent/EA202091120A3/ru unknown
- 2015-04-01 ES ES15713499.0T patent/ES2678046T3/es active Active
- 2015-04-01 CN CN201580018404.6A patent/CN106470991B/zh active Active
- 2015-04-01 PL PL15713499T patent/PL3125888T3/pl unknown
- 2015-04-01 LT LTEP18173541.6T patent/LT3388064T/lt unknown
- 2015-04-01 JP JP2016560727A patent/JP6745726B2/ja active Active
- 2015-04-01 LT LTEP15713499.0T patent/LT3125888T/lt unknown
- 2015-04-01 PT PT157134990T patent/PT3125888T/pt unknown
-
2016
- 2016-05-05 US US15/147,484 patent/US9782395B2/en active Active
- 2016-09-26 IL IL248037A patent/IL248037B/en active IP Right Grant
- 2016-10-03 CL CL2016002508A patent/CL2016002508A1/es unknown
- 2016-10-21 ZA ZA2016/07286A patent/ZA201607286B/en unknown
-
2017
- 2017-10-05 US US15/725,950 patent/US10179126B2/en active Active
-
2018
- 2018-07-23 CY CY20181100765T patent/CY1120454T1/el unknown
- 2018-12-13 US US16/218,829 patent/US20190255032A1/en not_active Abandoned
-
2020
- 2020-05-07 JP JP2020081949A patent/JP2020117539A/ja active Pending
-
2021
- 2021-03-30 HR HRP20210518TT patent/HRP20210518T1/hr unknown
- 2021-04-27 CY CY20211100363T patent/CY1124088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ725492A (en) | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders | |
| IL258862B (en) | N-[2-(1-Benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperidine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 antagonists for the treatment of neurological diseases | |
| FR24C1034I2 (fr) | Composés aryle, hétéroaryle et hétérocycliques pour le traitement de troubles induits par un complément | |
| PT3985002T (pt) | Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos | |
| DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
| IL246875A0 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
| MX2022003907A (es) | Compuestos y composiciones y usos de los mismos. | |
| PH12017500920A1 (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139 | |
| GEP20196949B (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| ZA202103106B (en) | Heterocyclic compounds for the treatment of epilepsy | |
| PH12015502676A1 (en) | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator | |
| PL3154939T3 (pl) | Sposób syntezy 2-(2,5-dimetylo-1h-pirol-1-ilo)-1,3-propanodiolu i jego podstawionych pochodnych | |
| MX2020013537A (es) | Compuestos de tiazolidinona y su uso en el tratamiento de trastornos psiquiatricos o neurologicos y de la inflamacion, en particular de la neuroinflamacion. | |
| IL249428B (en) | A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's | |
| HK40070316B (zh) | 用於治疗疾病的杂环化合物 | |
| HK40051477A (en) | Heterocyclic compounds for the treatment of epilepsy | |
| HK40053333A (en) | Methods for treating parkinson's disease by administering resiniferatoxin | |
| ZA201807944B (en) | Treatment for parkinson's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 APR 2025 BY THOMSON REUTERS Effective date: 20240305 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 APR 2026 BY THOMSON REUTERS Effective date: 20250307 |